Manufacturing and quality control data: the prosa® was manufactured by a qualified employee in january 2015.Deviations during assembly did not occur.The valve was sterilized by miethke and released for shipment after final inspection.The prosa® has a normal pressure range of 0 to 40 cmh2o.The valve was inspected as article fv701t.All parameters have been inspected and approved during the manufacturing process.All parameters have been assessed as meeting specifications.Incoming product condition: the valve was received submersed in an unidentified liquid in the provided returnkit.The complaint device was strongly contaminated with bloody liquid and tissue residues.Results: testing of contaminated valves are of limited value.The device characteristics may be influenced by the presence of cerebrospinal fluid or blood residues.As previously indicated, the complaint sample was received submerged in a bloody liquid and was contaminated with tissue residue.Subsequently, the device was classified as high risk to staff and for hygiene reasons, a device evaluation was not able to be performed.Therefore, a definitive conclusion regarding the complaint incident was unable to be reached without a physical examination of the complaint device.Although the device was not evaluated, it is possible that protein deposits inside the valve affected the function of the prosa® valve.As described in scientific literature, the problem encountered is one of the known, inevitable risks of hydrocephalus therapy (hc-therapy) by shunt implants.Manufacturing defects at the time of release have been excluded.The shunt system met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.
|
It was reported that a prosa valve (part # fv701t) was implanted during a procedure performed on (b)(6) 2017.According to the complainant, a blockage of the valve was suspected and the shunt system was believed to be operating in underdrainage.The patient underwent a revision procedure on (b)(6) 2021.The complaint device was returned to the manufacturer for evaluation.No patient complications were reported as a result of the revision procedure.Age: (b)(6), height: (b)(6), weight: (b)(6), gender: unknown.Same patient as # 3004721439-2021-00267.
|